Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS trials
Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbations reported as seri...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 April 2019
|
| In: |
Respiratory research
Year: 2019, Volume: 20, Pages: 1-7 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-019-1037-7 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12931-019-1037-7
|
| Author Notes: | Michael Kreuter, Harald Koegler, Matthias Trampisch, Silke Geier and Luca Richeldi |
| Summary: | Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbations reported as serious adverse events were associated with higher mortality than those reported as non-serious adverse events and to assess the effect of nintedanib on these types of events. |
|---|---|
| Item Description: | Gesehen am 22.05.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-019-1037-7 |